drugset / Trial / NCT05876312
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Phase 1/2
Recruiting
50 enrolled
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd · collabNovotech (Australia) Pty Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Timeline
- Start
- 2023-08-07
- Primary completion
- 2028-03-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |